AsianScientist (Nov. 17, 2015) – WuXi PharmaTech (Cayman) Inc. and Eli Lilly and Company have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.
The potential medicine is a novel, once-daily oral agent, discovered by Lilly, which could address cardiovascular risk in patients with dyslipidemia, representing an unmet medical need worldwide. An estimated 276 million patients in China are affected by these conditions, including about 12 million patients requiring drug treatment. The potential medicine aims to reduce cardiovascular events in patients with elevated low-density lipoprotein (LDL) cholesterol and triglycerides at high risk of cardiovascular events.
WuXi will be responsible for regulatory, development and manufacturing activities in China, which will be led and coordinated by WuXi’s Product Development Service and Partnership Business Unit. The potential medicine will be manufactured in China by WuXi, while Lilly will be responsible for commercial activities.
The parties will both invest in bringing this potential new medicine to patients in China. Further financial terms of the collaboration were not disclosed. An investigational new drug (IND) application will be filed in China by WuXi, and product development and registration will be carried out within China.
“This unique collaboration is part of our ‘In China, For China’ strategy to leverage Lilly’s leading technology and experience, and local partners’ insight and expertise, to meet patient needs,” said Mr. Andrew Hodge, President of Lilly China.
“This strategic collaboration will leverage the recently announced China regulatory reforms, which strongly encourage, support, and accelerate development and manufacture in China of highly innovative new medicines that target major unmet medical needs,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.
Source: WuXi AppTec;
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.